Recombinant Anti-CD20 x Anti-CD28 Bispecific Antibody (scFv-IgG) (BSSG-050)

Recombinant Anti-CD20 x Anti-CD28 Bispecific Antibody (scFv-IgG) is formed by an IgG and two scFv fragments. The scFvs from an anti-CD20 antibody variable domain are respectively connected to the N terminus of the anti-CD28 IgG heavy chains or light chains to form scFv-(H)IgG or scFv-(L)IgG. It is a type of appended IgGs and has 2+2 antigen-binding valency. This BsAb can retarget T cells to tumor cells. It is designed for the research of Lymphoma therapy.

Datasheet INQUIRY

Specifications

Targets

CD20 & CD28

Type

Appended IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Lymphoma

Targets

Target 1

CD20

Gene ID

931

UniProt ID

A0A024R507

Alternative Names

MS4A1; membrane-spanning 4-domains, subfamily A, member 1; B1; S7; Bp35; CD20; CVID5; MS4A2; LEU-16; B-lymphocyte antigen CD20; CD20 antigen; CD20 receptor; leukocyte surface antigen Leu-16; B-lymphocyte cell-surface antigen B1

Target 2

CD28

Gene ID

940

UniProt ID

P10747

Alternative Names

CD28; CD28 molecule; Cluster of Differentiation 28; Tp44; T-cell-specific surface glycoprotein CD28; CD28 antigen

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD20 x Anti-CD28 Bispecific Antibody (scFv-IgG) (BSSG-050). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD20 x Anti-CD28 Bispecific Antibody (scFv-IgG) (CAT#: BSSG-050)

Specifications

Targets

Customer Reviews and Q&As